Keywords: Genzyme, Cerezyme, Fabrazyme, Myozyme, EMEA, Suppy disruption

Further supply disruption of Genzyme's Cerezyme and Fabrazyme leads EMEA to give new temporary treatment recommendations; but no problems with Myozyme

Article | 23 April 2010

Print This

Troubled US biotech firm Genzyme has advised the European Union health regulator that the supply shortages of its rare disease ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in